A Texas woman who alleges that the Type 2 diabetes drug Actos caused her bladder cancer has filed a lawsuit against Takeda Pharmaceutical, the maker of Actos.
According to the complaint filed on her behalf, the plaintiff began taking Actos (pioglitazone) around May 2000 to help control her blood sugar and stopped taking the drug around June 2001, about which time she developed bladder cancer. The lawsuit alleges that the defendants knew that taking Actos could increase the risk of bladder cancer, but failed to disclose this information to her, her doctor, and other consumers. She is seeking damages for permanent injuries, for emotional distress, and for the medical and living expenses brought on by the cancer diagnosis.
Thousands of Actos lawsuits have been filed in state and federal courts across the country, according to an April 16 Bloomberg News report. The U.S. Food and Drug Administration (FDA) approved Actos, a Type 2 diabetes medication, in 1999. In 2011, the FDA required an update to the Actos label to warn users that they may face an increased risk of bladder cancer after taking the drug for only one year. Further research continues to confirm the risks of taking Actos for more than one year, including studies published in the British Medical Journal and the Canadian Medical Association Journal.
Parker Waichman LLP is representing the plaintiff in her suit, filed in April in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-0704) as part of a multidistrict litigation (In Re: Actos (Pioglitazone) Products Liability Litigation, MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the plaintiffs’ steering committee in the Actos MDL.